Paper Details

  1. Home
  2. Paper Details

Gemifloxacin: a new fluoroquinolone.

Author: BlondeauJoseph M, MissaghiBayan

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explores the in vitro activity and clinical efficacy of gemifloxacin, a dual-targeted fluoroquinolone, against various pathogens. Gemifloxacin demonstrates potent activity against clinically relevant organisms, including multi-drug resistant Streptococcus pneumoniae, and is approved for the treatment of community-acquired pneumonia and acute exacerbations of chronic bronchitis.
Paper Details　
Original Abstract of the Article :
Gemifloxacin is a dual targeted fluoroquinolone with potent in vitro activity against Gram-positive, -negative and atypical human pathogens--pathogens considered to be important causes of community-acquired respiratory tract infections. Gemifloxacin demonstrates impressive minimal inhibitory concent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14656566.5.5.1117

データ提供：米国国立医学図書館（NLM）

Gemifloxacin: A New Weapon in the Fight Against Respiratory Infections

Community-acquired respiratory tract infections (CARTIs) are a major cause of morbidity and mortality, especially in vulnerable populations. Fluoroquinolones, a class of antibiotics, have proven to be effective against a broad range of bacteria, but the emergence of antibiotic resistance poses a significant challenge. This research introduces gemifloxacin, a new fluoroquinolone, and evaluates its potential as a therapeutic agent for CARTIs.

Gemifloxacin's Potency: A Broad Spectrum of Activity

The research highlights gemifloxacin's potent in vitro activity against a wide range of Gram-positive, Gram-negative, and atypical human pathogens, many of which are responsible for CARTIs. The authors note that gemifloxacin's activity is not affected by beta-lactamase production or penicillin or macrolide resistance, making it a valuable tool for treating multi-drug resistant bacteria. This broad spectrum of activity, coupled with its once-daily oral administration, makes gemifloxacin a promising candidate for treating CARTIs.

A Promising Future: A New Weapon in the Antibiotic Arsenal

This research provides a comprehensive overview of gemifloxacin's efficacy, pharmacokinetics, and safety profile, suggesting its potential as a valuable addition to the antibiotic arsenal for treating CARTIs. The authors highlight its favorable efficacy and safety profile, particularly in comparison to other available agents. This research encourages further investigation into gemifloxacin's potential for treating other infections and its role in the ongoing battle against antibiotic resistance.

Dr. Camel's Conclusion

Imagine a desert landscape where a traveler is facing a fierce sandstorm. Gemifloxacin is like a sturdy camel, able to navigate the treacherous terrain and protect the traveler from the harsh elements. This new antibiotic can effectively target a wide range of bacteria, offering a strong defense against respiratory infections and paving the way for a healthier future.
Date :
  1. Date Completed 2004-10-14
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

15155113

DOI: Digital Object Identifier

10.1517/14656566.5.5.1117

Related Literature

Article Analysis
・Side Effects of gemifloxacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.